Reports Q3 revenue $799.5M, consensus $812.87M. “Our commercial and clinical teams continue to deliver record results, validating our strategic objectives,” said Martine Rothblatt, Chairperson and CEO of United Therapeutics (UTHR). “The breakthrough results from our TETON-2 study in idiopathic pulmonary fibrosis could significantly broaden our therapeutic reach and accelerate our growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- Notable companies reporting before tomorrow’s open
- United Therapeutics’ Promising Study on Inhaled Treprostinil for Lung Disease
- United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis
- United Therapeutics’ AI-Driven Study: A Potential Game-Changer for Pulmonary Hypertension Diagnosis
- United Therapeutics’ DeciPHer-ILD Study: A Closer Look at PH-ILD Patient Registry